Formulation development and evaluation of metoprolol succinate sustained release tablets using 32 factorial designFormulation development and evaluation of metoprolol succinate sustained release tablets using 32 factorial design

Available online at www.scholarsresearchlibrary.com
Scholars Research Library
Der Pharmacia Lettre, 2015, 7 (7):148-157
(http://scholarsresearchlibrary.com/archive.html)
ISSN 0975-5071
USA CODEN: DPLEB4
148
Scholar Research Library
Formulation development and evaluation of metoprolol succinate sustained
release tablets using 32
factorial design
J. N. Suresh Kumar1
, B. Satyaprasad2
, Gunji. Venkateswarlu3
, Chandan Kumar Brahma1
and Raghavendra Kumar Gunda1
*
1
Department of Pharmaceutics, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopet, Guntur (Dt),
Andhra Pradesh, India
2
Department of Pharmaceutical Analysis, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopet,
Guntur (Dt), Andhra Pradesh, India
3
Department of Pharmacognosy, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopet, Guntur (Dt),
Andhra Pradesh, India
_____________________________________________________________________________________________
ABSTRACT
The main objective of present investigation is to formulate the sustained release tablet of Metoprolol Succinate
using 32
factorial design. Metoprolol Succinate, is a selective β1blocker, to treat Hypertension & Heart Failure. The
SR tablets of Metoprolol Succinate were prepared employing different concentrations of HPMCK15M and
HPMCK100M in different combinations as a rate retardants by Direct Compression technique using 32
factorial
design. The quantity of rate retarders, HPMCK15M and HPMCK100M required to achieve the desired drug release
was selected as independent variables, X1 and X2 respectively whereas, time required for 10% of drug dissolution
(t10%), 50% (t50%), 75% (t75%) and 90% (t90%) were selected as dependent variables. Totally nine formulations were
designed and are evaluated for hardness, friability, thickness, % drug content, In-vitro drug release. From the
Results it was concluded that all the formulation were found to be with in the Pharmacopoeial limits and the In-
vitro dissolution profiles of all formulations were fitted in to different Kinetic models, the statistical parameters like
intercept (a), slope (b) & regression coefficient (r) were calculated. Polynomial equations were developed for t10%,
t50%, t75%, t90%. Validity of developed polynomial equations were verified by designing 2 check point formulations(C1,
C2). According to SUPAC guidelines the formulation (F5) containing combination of 10% HPMCK15M and 10%
HPMCK100M, is the most similar formulation (f2=92.38 & No significant difference, t= 0.0216) to marketed
product (Metocard). The selected formulation (F5) follows Higuchi’s kinetics, the mechanism of drug release was
found to be Super case II transport (Non-Fickian, n= 0.981).
Keywords: Metoprolol Succinate, Factorial Design, Sustained Release Tablet, HPMCK15M, HPMCK100M, Non
Fickian Mechanism, Super Case-II Transport.
_____________________________________________________________________________________________
INTRODUCTION
Oral administration is the most convenient, widely utilized for both conventional and novel drug delivery systems,
and preferred route of drug delivery for systemic action. Tablets are the most popular oral solid formulations
available in the market and are preferred by patients and physicians alike. There are many obvious reasons for this,
not the least of which would include acceptance by the patient and ease of administration . In long-term therapy for
the treatment of chronic disease conditions, conventional formulations are required to be administered in multiple
doses and therefore have several disadvantages [1]. However, when administered orally, many therapeutic agents are
subjected to extensive presystemic elimination by gastrointestinal degradation and/or first pass hepatic metabolism
as a result of which low systemic bioavailability and shorter duration of therapeutic activity and formation of
inactive or toxic metabolites [2].

Raghavendra Kumar Gunda et al Der Pharmacia Lettre, 2015, 7 (7):148-157
______________________________________________________________________________
149
The concept of regulating drug delivery in the human body has been in existence for many years because of major
benefits such as improved patient compliance and decreased side effects. Many innovative methods have been
developed in the last few years for obtaining modified drug release.
Over the past 30 years, as the expense and complications involved in marketing new drug entities have increased,
with concomitant recognition of the therapeutic advantages of controlled drug delivery, the goal in the designing
sustained –or controlled delivery system is to reduce the frequency of dosing or to increase effectiveness of the drug
by localization at the site of action, reducing the dose required, or providing uniform drug delivery [3].
Sustained release dosage forms may be defined as any drug or dosage form modification that prolonged but not
necessarily uniform release of drug. The goal of a sustained release dosage form is to maintain therapeutic blood or
tissue levels of the drug for an extended period. This is usually accomplished by attempting to obtain zero-order
release from the dosage form. Zero-order release constitutes the drug release from the dosage form that is
independent of the amount of drug in the delivery system (i. e., constant release rate). Sustained release systems
generally do not attain this type of release and usually try to mimic zero-order release by providing drug in a slow
first-order fashion (i. e., concentration dependent). Systems that are designated as prolonged release can also be
considered as attempts at achieving sustained release delivery [4,5].
Sustained release tablet allowing a 2 fold or greater reduction in frequency of administration of a drug in comparison
with the frequency required by a conventional dosage form [6,7]. Sustained release products provide advantage over
conventional dosage form by optimising biopharmaceutics, pharmacokinetics and pharmacokinetics properties of
drug. Sustained release dosage forms have been demonstrated to improve therapeutic efficiency by maintenance of
a steady drug plasma concentration [8,9].
Oral controlled drug delivery system represents one of the frontier areas of drug delivery system in order to fulfill
the need for a long-term treatment with anti-HIV agents [10]. Among the different controlled drug delivery (CDD)
systems, matrix based controlled release tablet formulations are the most popularly preferred for its convenience to
formulate a cost effective manufacturing technology in commercial scale. Development of oral controlled release
matrix tablets containing water-soluble drug has always been a challenging because of dose dumping due to
improper formulation resulting in plasma fluctuation and accumulation of toxic concentration of drug [11]. The use
of polymers in controlling the release of drugs has become an important tool in the formulation of pharmaceutical
dosage forms. Over many years, numerous studies have been reported in the literature on the application of
hydrophilic polymers in the development of controlled release matrix systems for various drugs [12,13,14].
Since the early 1950s, the application of polymeric materials for medical purposes is growing very fast. Polymers
have been used in the medical field for a large extent [15]. Natural polymers remain attractive primarily because
they are inexpensive, readily available, be capable of chemical modifications, non-carcinogenicity, mucoadhesivity,
biodegradable, biocompatible, high drug holding capacity and high thermal stability and easy of compression [16].
This led to its application as excipient in hydrophilic drug delivery system. The various natural gums and mucilages
have been examined as polymers for sustained drug release in the last few decades for example; guar gum,
tragacanth gum, Xanthan Gum, pectin, alginates etc, Hydrophilic polymers such as hydroxypropyl methylcellulose
(HPMC), hydroxypropylcellulose, chitosan, carbomer in the development of a sustained release tablet dosage form.
These dosage forms are available in extended release, targeted release, delayed release, prolonged action dosage
form. Some factors like molecular size, diffusivity, pKa-ionization constant, release rate, dose and stability, duration
of action, absorption window, therapeutic index, protein binding, and metabolism affect the design of sustained
release formulation. The future of sustained release products is promising in some area like chronopharmacokinetic
system, targeted drug delivery system, mucoadhesive system, particulate system that provide high promise and
acceptability.
Developing oral-sustained release formulations for highly water-soluble drugs with constant rate of release has
become a challenge to the pharmaceutical technologists. Fast release drug generally causes toxicity if not formulated
as extended release dosage form. Among various formulation approaches, in controlling the release of water-soluble
drugs, the development of sustained release coated granules has a unique advantage of lessening the chance of dose
dumping which is a major problem when highly water-soluble drug is formulated as matrix tablets. Most of the
researchers have worked on matrix tablets and multilayered matrix tablets. Among numerous approaches to oral SR
formulation, matrix system of dosage form proves to be potential because of its simplicity, ease of manufacturing,
low cost, high level of reproducibility, stability, ease of scale up, and process validation [17].

______________________________________________________________________________
150
Oral sustained release dosage form by direct compression technique is a simple approach of drug delivery systems
that proved to be rational in the pharmaceutical arena for its ease, compliance, faster production, avoid hydrolytic or
oxidative reactions occurred during processing of dosage forms [18].
The selection of the drug candidates for sustained release system needs consideration of several biopharmaceutical,
pharmacokinetic and pharmacodynamic properties of drug molecule [19].
In the present study, a sustained release dosage form of Metoprolol Succinate has been developed that enables less
frequent administering of drug.
Cardiovascular functions such as heart rate (HR) and blood pressure (BP) show 24 h variation. The incidence of
cardiovascular diseases such as acute myocardial infarction, strokes and arrhythmia also exhibits clear diurnal
oscillation. Since most of these disorders can induce fatal or severe outcomes, it is important to elucidate the precise
mechanism of the onset of these diseases. This circadian occurrence is believed to be tightly associated with an
internal clock.
Metoprolol ((+)-1-(isopropyl amino)-3-[p-(2-methoxyethyl)]- 2-propanol succinate) is a selective beta-adrenergic
receptor blocker useful in treatment of hypertension, angina and heart failure. Metoprolol succinate is a white
crystalline powder with high aqueous solubility and high permeability throughout gastrointestinal tract [20]. Half-
life of metoprolol succinate ranges from 3 to 7 h [21].
Development of dosage form depends on chemical nature of the drug/polymers, matrix structure, swelling,
diffusion, erosion, release mechanism and the in vivo environment.
It is an important issue is to design an optimized formulation with an appropriate dissolution rate in a short time
period and minimum trials. Many statistical experimental designs have been recognized as useful techniques to
optimize the process variables. For this purpose, response surface methodology (RSM) utilizing a polynomial
equation has been widely used. Different types of RSM designs include 3-level factorial design, central composite
design (CCD), Box-Behnken design and D-optimal design. Response surface methodology (RSM) is used when
only a few significant factors are involved in experimental optimization. The technique requires less
experimentation and time, thus proving to be far more effective and cost-effective than the conventional methods of
formulating sustained release dosage forms [22] .
Hence an attempt is made in this research work to formulate Sustained release (SR) Tablets of Metoprolol Succinate
using HPMCK15M and HPMCK100M. Instead of normal and trial method, a standard statistical tool design of
experiments is employed to study the effect of formulation variables on the release properties.
Large scale production needs more simplicity in the formulation with economic and cheapest dosage form. The SR
tablets formulation by direct compression method is most acceptable in large scale production.
A 32
full factorial design was employed to systematically study the drug release profile . A 32
full factorial design
was employed to investigate the effect of two independent variables (factors), i.e the amounts of HPMCK15M and
HPMCK100M on the dependent variables, i.e. t10%, t50%, t75%, t90%, ( Time taken to release 10%,50%,75%,90%
respectively)
MATERIALS AND METHODS
Materials used in this study were obtained from the different sources. Metoprolol Succinate was a gift sample from
Aurobindo pharma Ltd, Hyderabad, India. HPMCK15M , HPMCK100M, Di Calcium Phosphate and Micro
Crystalline Cellulose were procured from Loba Chemie Pvt.Ltd, Mumbai. Other excipients such as Talc and
magnesium stearate were procured from S.D. Fine Chem. Ltd., Mumbai.
Formulation Development of Metoprolol Succinate Sustained Release Tablets:
The factorial design is a technique that allows identification of factors involved in a process and assesses their
relative importance. In addition, any interaction between factors chosen can be identified. Construction of a factorial
design involves the selection of parameters and the choice of responses [23] .
A selected three level, two factor experimental design (32
factorial design) describe the proportion in which the
independent variables HPMCK15M and HPMCK100M were used in formulation of Metoprolol Succinate sustained
release (SR) Tablets. The time required for 10% (t10%), 50% (t50%), 75% (t75%) and 90% (t90%) drug dissolution were

______________________________________________________________________________
151
selected as dependent variables. Significance terms were chosen at 95% confidence interval (p<0.05) for Final
Equations. Polynomial equations were developed for t10%, t50%, t75%, t90%, (step-wise backward Linear Regression
Analysis).
The three levels of factor X1 (HPMCK15M) at a concentration of 5%, 10%, 15%. three levels of factor X2
(HPMCK100M) at a concentration of 5%, 10%, 15%.(% with respect to total tablet weight) was taken as the
rationale for the design of the Metoprolol Succinate SR tablet formulation. Totally 9 Metoprolol Succinate sustained
release tablet formulations were prepared employing selected combinations of the two factors i.e X1, X2 as per 32
Factorial and evaluated to find out the significance of combined effects of X1, X2 to select the best combination and
the concentration required to achieve the desired prolonged/ sustained release of drug from the dosage form.
Preparation of Metoprolol Succinate Sustained Release Tablets:
All ingredients were collected and weighed accurately. Sift Metoprolol Succinate with Microcrystalline Celulose
and polymers through sieve no. 44# and then rinse with remaining excipients. Sift colloidal silicon dioxide (Aerosil-
200) and magnesium stearate separately, through sieve no. 60#. Pre-blend all ingredients (except lubricant-
magnesium stearate) in blender for 15 minutes. Add magnesium stearate and then again blend for 5-6 minutes.
Lubricated powder was compressed by using rotary tablet punching machine (RIMEK), Ahmedabad). Compressed
tablets were examined as per official standards and unofficial tests. Tablets were packaged in well closed light
resistance and moisture proof containers.
Experimental Design:
Experimental design utilized in present investigation for the optimization of polymer concentration such as,
concentration of HPMCK15M was taken as X1 and concentration of HPMCK100M was taken as X2. Experimental
design was given in the Table 1. Three levels were selected and coded as -1= 5%, 0=10%, +1=15%. Formulae for all
the experimental batches were given in Table 2 [24,25].
TABLE 1: EXPERIMENTAL DESIGN LAYOUT
Formulation
Code
X1 X2
F1 1 1
F2 1 0
F3 1 -1
F4 0 1
F5 0 0
F6 0 -1
F7 -1 1
F8 -1 0
F9 -1 -1
C1 -0.5 -0.5
C2 +0.5 +0.5
TABLE 2: FORMULAE FOR THE PREPARATION OF METOPROLOL SUCCINATE SUSTAINED RELEASE TABLETS AS PER
EXPERIMENTAL DESIGN
Name of Ingredients
Quantity of Ingredients per each Tablet (mg)
F1 F2 F3 F4 F5 F6 F7 F8 F9
Metoprolo Succinate 100 100 100 100 100 100 100 100 100
Microcrystalline Cellulose 30 30 30 30 30 30 30 30 30
HPMCK15M 60 60 60 40 40 40 20 20 20
HPMCK100M 60 40 20 60 40 20 60 40 20
Di Calcium Phosphate 132 152 172 152 172 192 172 192 212
Talc 9 9 9 9 9 9 9 9 9
Magnesium Stearate 9 9 9 9 9 9 9 9 9
Total Weight 400 400 400 400 400 400 400 400 400
EVALUATION OF METOPROLOL SUCCINATE SUSTAINED RELEASE TABLETS:
Hardness [25]
The hardness of the tablets was tested by diametric compression using a Monsanto Hardness Tester. A tablet
hardness of about 2-4 kg/cm2
is considered adequate for mechanical stability.
Friability [25]
The friability of the tablets was measured in a Roche friabilator (Camp-bell Electronics, Mumbai). Tablets of a
known weight (W0) or a sample of 20 tablets are dedusted in a drum for a fixed time (100 revolutions) and weighed

______________________________________________________________________________
152
(W) again. Percentage friability was calculated from the loss in weight as given in equation as below. The weight
loss should not be more than 1 %
Friability (%) = [(Initial weight- Final weight) / (Initial weight)] x 100
Content Uniformity [25]
In this test, 20 tablets were randomly selected and the percent drug content was determined, the tablets contained not
less than 85% or more than 115% of the labelled drug content can be considered as the test was passed.
Assay
Weighed and finely powdered not less than 20 tablets were taken and transfer an accurately weighed portion of the
powder equivalent to about 100 mg of Metoprolol Succinate was extracted with 0.1N Hcl and the solution was
filtered through 0.45 µ membranes. The absorbance was measured at 274 nm after suitable dilution using UV-visible
spectrophotometer.
Thickness and Diameter [25]
Thickness of the all tablet formulations were measured using vernier calipers by placing tablet between two arms of
the vernier calipers. The same procedure should be adapted for the measurement of Diameter.
In-vitro Dissolution Study:
The In-vitro dissolution study for the Metoprolol Succinate sustained release tablets were carried out in USP
XXIII type-II dissolution test apparatus (Paddle type) using 900 ml of 0.1 N HCl as dissolution medium at 75 rpm
and temperature 37±0.5°C. At predetermined time intervals, 5 ml of the samples were withdrawn by means of a
syringe fitted with a pre-filter, the volume withdrawn at each interval was replaced with same quantity of fresh
dissolution medium. The resultant samples were analyzed for the presence of the drug release by measuring the
absorbance at 274 nm using UV Visible spectrophotometer after suitable dilutions. The determinations were
performed in triplicate.
Kinetic modeling of drug release:
The dissolution profile of all the formulations was fitted in to zero-order, first-order, Higuchi and Korsmeyer-peppas
models to ascertain the kinetic modeling of drug release [26,27,28].
RESULTS AND DISCUSSION
Sustained release tablets of Metoprolol Succinate were prepared and optimized by 32
factorial design in order to
select the best combination of different rate retarding agents, HPMCK15M, HPMCK100M and also to achieve the
desired prolong/sustained release of drug from the dosage form. The two factorial parameters involved in the
development of formulations are, quantity of HPMCK15M & HPMCK100M polymers as independent variables (X1,
X2), and In vitro dissolution parameters such as t10%, t50% , t75% & t90% as dependent variables. Totally nine
formulations were prepared using 3 levels of 2 factors and all the formulations containing 100 mg of Metoprolol
Succinate were prepared as a sustained release tablet dosage form by Direct Compression technique as per the
formulae given in Table 2.
All the prepared tablets were evaluated for different post compression parameters, drug content, mean hardness,
friability, mean thickness as per official methods and results were given in Table 3. The hardness of tablets was in
the range of 7.96-9.85 Kg/cm2
. Weight loss in the friability test was less than 0.69%. Drug content of prepared
tablets was within acceptance range only. Results for all Post-compression parameters were tabulated or shown in
Table 3. In-vitro Dissolution studies were performed for prepared tables using 0.1 N HCl as a dissolution media at
75 rpm and temperature 37±0.5°C. The In-vitro dissolution profiles of tablets are shown in Fig.1 and the dissolution
parameters are given in Table 4. Cumulative % Drug release of Factorial Design Formulations F1-F9 at 12Hr were
found to be in the range of 80.48-97.84 %. From the result it reveals that the release rate was higher for
formulations containing Low level of HPMCK15M / HPMCK100M compared with other Formulations containing
Higher level, due to High concentration of polymer drug may have entrapped within a polymer matrix causing a
decrease in rate of drug release. Therefore, required release of drug can be obtained by manipulating the
composition of HPMCK15M and HPMCK100M.
Much variation was observed in the t10% , t50%, t75% and t90% due to formulation variables. Formulation F5 containing
40 mg of HPMCK15M, 40 mg of HPMCK100M showed promising dissolution parameter (t10%= 0.564h, t50% = 3.713
h, t75% = 7.426 h, t90% = 12.339 h). The difference in burst effect of the initial time is a result of the difference in the

______________________________________________________________________________
153
viscosity of the polymeric mixtures. Dortunc and Gunal have reported that increased viscosity resulted in a
corresponding decrease in the drug release, which might be due to the result of thicker gel layer formulation [29] .
The In -vitro dissolution data of Metoprolol Succinate SR formulations was subjected to goodness of fit test by
linear regression analysis according to zero order, first order kinetic equations, Higuchi’s and Korsmeyer-Peppas
models to assess the mechanism of drug release. The results of linear regression analysis including regression
coefficients were summarized in Table 4 and plots shown in fig.1,2,3,4. It was observed from the above, that
dissolution of all the tablets followed First order kinetics with co-efficient of determination (R2
) values above 0.990.
The values of r of factorial formulations for Higuchi’s equation was found to be in the range of 0.987-0.994, which
shows that the data fitted well to Higuchi’s square root of time equation confirming the release followed diffusion
mechanism. Kinetic data also treated for Peppas equation, the slope (n) values ranges from 0.882- 1.025 that shows
Non-Fickian diffusion mechanism (Super Case-II transport). Polynomial equations were derived for t10%, t50%, t75%
and t90% values by backward stepwise linear regression analysis. The dissolution data (Kinetic Parameters) of
factorial formulations F1 to F9 are shown in Table 5.
Polynomial equation for 3² full factorial designs is given in Equation
Y= b0+b1 X1+b2 X2+b12 X1X2+b11 X1²+b22 X2²…
Where, Y is dependent variable, b0 arithmetic mean response of nine batches, and b1 estimated co-efficient for factor
X1. The main effects (X1 and X2) represent the average result of changing one factor at a time from its low to high
value. The interaction term (X1X2) shows how the response changes when two factors are simultaneously changed.
The polynomial terms (X1² and X2²) are included to investigate non-linearity. Validity of derived equations was
verified by preparing Two Check point Formulations of Intermediate concentration(C1, C2) using -0.50,+0.50.
The equations for K1, t10% and t50% developed as follows,
Y1= 0.581+0.158X1+0.0585X2+0.003X1X2+0.0182X1
2
+0.000167X2
2
(for t10%)
Y2= 3.825+1.037X1+0.384X2+0.020X1X2+0.118X1
2
+0.0007X2
2
(for t50%)
Y3= 7.651+2.073X1+0.769X2+0.039X1X2+0.235X1
2
+0.0013X2
2
(for t75%)
Y4 = 12.712+3.444X1+1.278X2+0.065X1X2+0.391X1
2
+0.002X2
2
(for t90%)
The positive sign for co-efficient of X2 in Y1, Y2, Y3 and Y4 equations indicates that, as the concentration of
HPMCK100M increases, t10%, t50%, t75% and t90% value increases. In other words the data demonstrate that both X1
(amount of HPMCK15M) and X2 (amount of HPMCK100M) affect the time required for drug release (t10%, t50%, t75%
and t90%). From the results it can be concluded that, and increase in the amount of the polymer leads to decrease in
release rate of the drug and drug release pattern may be changed by appropriate selection of the X1 and X2 levels.
The Dissolution parameters for predicted from the polynomial equatio0ns derived and those actual observed from
experimental results are summarised in Table 6. The closeness of Predicted and Observed values for t10%, t50%, t75%
and t90% indicates validity of derived equations for dependent variables. The Contour Plots were presented to show
the effects of X1 and X2 on t10%, t50%, t75% and t90%. The final best (Optimised) formulation (F5) is compared with
marketed product (Metocard) shows similarity factor (f2) 92.38, difference factor (f1) 1.77 (There is no significant
difference in drug release because tcal is<0.05).
TABLE 3: POST-COMPRESSION PARAMETERS FOR THE FORMULATIONS
S.No.
Formulation
Code
Hardness
(kg/cm2
)
Diameter (mm)
Thickness
(mm)
Friability (%) DRUG CONENT (%)
1 F1 9.65 12.66 4.53 0.46 99.86
2 F2 9.14 12.62 4.42 0.55 98.07
3 F3 9.24 12.53 4.53 0.55 97.64
4 F4 9.47 11.98 4.52 0.58 98.37
5 F5 9.85 11.90 4.24 0.62 96.23
6 F6 9.85 11.87 4.28 0.67 98.30
7 F7 9.53 11.57 4.43 0.60 99.27
8 F8 7.96 11.68 4.33 0.69 92.81
9 F9 8.55 11.20 4.28 0.55 95.14

______________________________________________________________________________
154
Fig.1 Comparative Zero Order Plots of F1-F9 Fig.2 Comparative First Order Plots of F1-F9
Fig.3 Comparative Higuchi Plots of F1-F9 Fig.4 Comparative Korsmeyer-Peppas Plots
Fig.5 Linear Contour Plot for t10% Fig.6 Contour Plot for t10%

______________________________________________________________________________
155

______________________________________________________________________________
156
TABLE 4: REGRESSION ANALYSIS DATA OF 32
FACTORIAL DESIGN FORMULATIONS OF METOPROLOL SUCCINATE
F1 to F9 are factorial formulations, r-correlation coefficient, a-Intercept, b-Slope and MP-Marketed Product.
TABLE 5: DISSOLUTION PARAMETERS OF METOPROLOL SUCCINATE SUSTAINED RELEASE TABLETS 3² FULL
FACTORIAL DESIGN BATCHES
S.NO
FORMULATION
CODE
KINETIC PARAMETERS
t10% (h) t50% (h) t75% (h)) t90% (h)
1 F1 0.828 5.445 10.890 18.093
2 F2 0.746 4.907 9.814 16.305
3 F3 0.661 4.352 8.703 14.460
4 F4 0.587 3.863 7.726 12.836
5 F5 0.564 3.713 7.426 12.339
6 F6 0.557 3.665 7.330 12.178
7 F7 0.505 3.322 6.645 11.040
8 F8 0.434 2.855 5.710 9.487
9 F9 0.351 2.307 4.614 7.666
10 MP 0.549 3.615 7.230 12.012
TABLE 6: DISSOLUTION PARAMETERS FOR PREDICTED AND OBSERVED VALUES FOR CHECK POINT FORMULATIONS
FORMULATION CODE PREDICTED VALUE ACTUAL OBSERVED VALUE
t10% (h) t50% (h) t75% (h)) t90% (h) t10% (h) t50% (h) t75% (h)) t90% (h)
C1 0.478 3.149 6.30 10.47 0.481 3.147 6.298 10.476
C2 0.694 4.570 9.14 15.19 0.697 4.568 9.139 15.188
CONCLUSION
The present research work envisages the applicability of rate retarding agents such as HPMCK15M and
HPMCK100M in the design and development of sustained release tablet formulations of Metoprolol Succinate
utilizing the 32
factorial design. From the results it was clearly understand that as the retardant concentration
increases the release rate of drug was retarded and both of these polymers can be used in combination since do not
interact with the drug which may be more helpful in achieving the desired sustained release of the drug for longer
periods. The optimized formulations followed Higuchi’s kinetics while the drug release mechanism was found to be
Non Fickian Diffusion (Super Case-II transport), controlled by diffusion through the swollen matrix. On the basis of
evaluation parameters, the optimized formulation F5 may be used once a day administration in the management of
Hypertension, Angina and other Cardiac problems
Acknowledgements
The authors would like to thank Management, Principal, Teaching, Non-teaching Staff of Narasaraopeta Institute of
Pharmaceutical Sciences, Narasaraopet, Guntur (D.t), A.P., India for providing support for successful completion of
research work.
REFERENCES
[1] Swati Jain, Neelesh Kumar Mehra, Akhlesh Kumar Singhai and Gaurav Kant Saraogi, IJPSR, 2011; Vol. 2(1):
454-461.
[2] R. Ruben Singh, International Journal of Research in Pharmaceutical and Nano Sciences. 2014; 3(2): 113 –
121.
[3] Y. Ganesh kumar, J. Sreekanth, D. Satyavati, Int J Pharm Pharm Sci. 2014; 6( 11): 111-118.
[4] Bankar GS, Rhodes CT. Eds. Modern Pharmaceutics. 3
rd
edn. Marcel Dekker, Inc. New York. 1996; 668-9.
S.NO
Formulation
Code
KINETIC PARAMETERS
ZERO ORDER FIRST ORDER HIGUCHI KORSMEYER-PEPPAS
a b r a b r a b r a b r
1 F1 10.956 6.154 0.966 1.982 0.055 0.991 3.04 23.36 0.994 0.882 1.053 0.908
2 F2 13.032 6.380 0.953 1.974 0.061 0.991 2.045 24.537 0.994 0.914 1.053 0.898
3 F3 13.510 6.701 0.951 1.979 0.069 0.994 2.409 25.821 0.993 0.916 1.077 0.895
4 F4 17.110 6.901 0.927 1.958 0.078 0.994 0.287 27.153 0.989 0.969 1.059 0.879
5 F5 18.021 6.944 0.921 1.954 0.081 0.994 0.278 27.454 0.986 0.981 1.057 0.873
6 F6 20.290 6.874 0.901 1.934 0.082 0.986 2.021 27.572 0.980 1.009 1.038 0.865
7 F7 14.514 7.235 0.955 2.003 0.091 0.996 2.570 27.820 0.996 0.938 1.087 0.895
8 F8 19.478 7.242 0.924 1.985 0.105 0.996 0.971 28.634 0.990 1.004 1.054 0.871
9 F9 21.301 7.353 0.915 2.014 0.130 0.986 2.128 29.286 0.987 1.025 1.048 0.867
10 MP 18.311 6.968 0.923 1.956 0.083 0.995 0.528 27.537 0.988 0.989 1.050 0.872

______________________________________________________________________________
157
[5] Lachmann L, Lieberman HA, Kanig JL. The Theory & Practice of Industrial Pharmacy. 3rd
Edition Varghese
Publishing House, Bombay. 1991. p. 430.
[6] VNL. Sirisha*, Y. Kiran Kumarrao and M. Chinna Eswaraiah, International Journal of Research in
Pharmaceutical and Biomedical Sciences. 2012; 3 (4): 1759-1763.
[7] John C and Morten C. The Science of Dosage Form Design, Aulton: Modified release peroral dosage forms, 2nd
ed Churchill Livingstone. 2002;290-300.
[8] Turner S, Federici C, Hite M, Fassihi R, Drug Dev Ind Pharm. 2004;30(8):797-807.
[9] Fernandes CM, Ramos P, Amilcar CF, Veiga FB, J. Control.Release. 2003; 88(1): 127-134.
[10] Atul K, Ashok KT, Narendra KJ, Subheet J, AAPS Pharm Sci Tech. 2006;7(1):E1-E9.
[11] Al-saidan SM, Krishnaiah YSR, Patro S, Satyaranayana V, AAPS Pharm Sci Tech. 2005;6 (1):E14-E21.
[12] Ravi PR, Ganga S, Saha RN , AAPS Pharm Sci Tech 2007;8 (4):167-75.
[13] Badshah A, Subhan F, Shah NH, Bukhari NI, Saeed M Shah KU, Drug Dev Ind Pharm .2012;38 (2):190-9.
[14] Singh B, Rani A, Babita, Ahuja N, Kapil R, Sci Pharm 2010;78 (2):303-23.
[15] Ravi PR, Ganga S, Saha RN, J American Association of Pharm Scientists Pharm Sci Tech. 2007;8 (4):1-9.
[16]Prakash P, Porwal M, Saxena A, Int Res J of Pharmacy. 2011;2(9):6-11.
[17]Abdul S.Althaf, Der Pharmacia Sinica. 2010;1(2): 61-76.
[18]Amidon, GL and R Löbenberg, Eur. J. Pharm. Biopharm 2000; 50: 3–12.
[19]Bankar GS, Rhodes CT. Eds. Modern Pharmaceutics, 4th ed. Marcel Dekker.2003; 503-505.
[20]L. Raimar, K. Jae Seung, and L. A. Gordon, Eur. J. Pharm. Biopharm.2000; 60:17–23.
[21]J. Wikstrand, B. Andersson, M. Kendall, H. Stanbrook, M. Klibaner, J. Cardiovascular Pharmacology. 2003;
41:151–157.
[22]M.A.Shende, R.P.Marathe, S.B. Khetmalas, P. Dhabale, International journal of pharmacy and
pharmaceutical sciences. 2014; 6(7): 72-78.
[23]A. A. Kharia, s. N. Hiremath, a. K. Singhai, K. Omray and S. K. Jain, Indian J. Pharm. Sci. 2010; 72 (5): 599-
606.
[24]Ramesh C. Nagarwal, AAPS PharmSciTech. 2009; 10(3): 977-984.
[25]Raghavendra Kumar Gunda, J. N. Suresh Kumar, Ch Ajay Babu and M. V. Anjaneyulu, IJPSR, 2015; 6(4):
1746-1752.
[26]Notari RE. Biopharmaceutics and clinical pharmacokinetics. 4th ed. New York: Marcel Dekker Inc; 1987; 6-21.
[27]Higuchi T, J Pharm Sci. 1963; 51:1145-9.
[28]Peppas NA , Pharm Acta Helv 1985; 60:110-1.
[29]Dortunc B, Gunal N, Drug Dev Ind Pharm. 1997; 23:1245-9.

Formulation development and evaluation of metoprolol succinate sustained release tablets using 32 factorial designFormulation development and evaluation of metoprolol succinate sustained release tablets using 32 factorial design

More Related Content

What's hot (20)

Viewers also liked (6)

Similar to Formulation development and evaluation of metoprolol succinate sustained release tablets using 32 factorial designFormulation development and evaluation of metoprolol succinate sustained release tablets using 32 factorial design (20)

More from Dr. Raghavendra Kumar Gunda (20)

Recently uploaded (20)

Formulation development and evaluation of metoprolol succinate sustained release tablets using 32 factorial designFormulation development and evaluation of metoprolol succinate sustained release tablets using 32 factorial design